Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Scherübl H[au]:

Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance. Scherübl H et al. Visc Med. (2017)

Neuroendocrine Tumors of the Gastrointestinal Tract. Bartsch DK et al. Visc Med. (2017)

[Rectal neuroendocrine tumors: endoscopic therapy]. Eick J et al. Chirurg. (2016)

Search results

Items: 1 to 50 of 157

1.

[Alcohol Use and Cancer Risk].

Scherübl H.

Dtsch Med Wochenschr. 2019 Sep;144(19):1354-1360. doi: 10.1055/a-0928-0586. Epub 2019 Sep 26. German.

PMID:
31559617
2.

[Neuroendocrine tumors : Classification, clinical presentation and imaging].

Scherübl H, Raue F, Frank-Raue K.

Radiologe. 2019 Nov;59(11):952-960. doi: 10.1007/s00117-019-0574-x. Review. German.

PMID:
31359091
3.

Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance.

Scherübl H, Cadiot G.

Visc Med. 2017 Oct;33(5):332-338. doi: 10.1159/000459404. Epub 2017 Oct 10. Review.

4.

Neuroendocrine Tumors of the Gastrointestinal Tract.

Bartsch DK, Scherübl H.

Visc Med. 2017 Oct;33(5):321-322. doi: 10.1159/000481766. Epub 2017 Oct 16. No abstract available.

5.

[Rectal neuroendocrine tumors: endoscopic therapy].

Eick J, Steinberg J, Schwertner C, Ring W, Scherübl H.

Chirurg. 2016 Apr;87(4):288-91. doi: 10.1007/s00104-015-0141-6. Review. German.

PMID:
26801755
6.

[What is new in treating Helicobacter pylori infection?].

Scherübl H, Fischbach W, Glocker E, Malfertheiner P.

Dtsch Med Wochenschr. 2015 Feb;140(4):277-80. doi: 10.1055/s-0041-100463. Epub 2015 Feb 19. Review. German.

PMID:
25704525
7.

Therapy of rectal carcinoids of 11 to 19 mm: a matter of debate.

Scherübl H, de Mestier L, Cadiot G.

Gastrointest Endosc. 2014 Sep;80(3):532-3. doi: 10.1016/j.gie.2014.03.009. No abstract available.

PMID:
25127951
8.

Management of early asymptomatic gastrointestinal stromal tumors of the stomach.

Scherübl H, Faiss S, Knoefel WT, Wardelmann E.

World J Gastrointest Endosc. 2014 Jul 16;6(7):266-71. doi: 10.4253/wjge.v6.i7.266.

9.

Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.

Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM.

World J Gastroenterol. 2013 Dec 21;19(47):9012-9. doi: 10.3748/wjg.v19.i47.9012.

10.

[Early asymptomatic GIST of the stomach].

Scherübl H, Faiss S, Jahn HU, Knoefel WT, Liehr RM, Schwertner C, Steinberg J, Stölzel U, Weinke T, Zimmer T, Wardelmann E.

Dtsch Med Wochenschr. 2012 Aug;137(33):1650-3. doi: 10.1055/s-0032-1305210. Epub 2012 Aug 8. Review. German. No abstract available.

PMID:
22875693
11.

Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.

Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M.

Int J Oncol. 2012 May;40(5):1659-67. doi: 10.3892/ijo.2012.1328. Epub 2012 Jan 10.

PMID:
22246317
12.

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.

Raoul JL, Bruix J, Greten TF, Sherman M, Mazzaferro V, Hilgard P, Scherubl H, Scheulen ME, Germanidis G, Dominguez S, Ricci S, Nadel A, Moscovici M, Voliotis D, Llovet JM.

J Hepatol. 2012 May;56(5):1080-8. doi: 10.1016/j.jhep.2011.12.009. Epub 2012 Jan 13.

PMID:
22245896
13.

Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.

Mayer P, Harjung A, Breinig M, Fischer L, Ehemann V, Malz M, Scherübl H, Britsch S, Werner J, Kern MA, Bläker H, Schirmacher P, Bergmann F.

Endocr Relat Cancer. 2012 May 3;19(3):217-32. doi: 10.1530/ERC-11-0227. Print 2012 Jun.

PMID:
22194440
14.

AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.

Gloesenkamp CR, Nitzsche B, Ocker M, Di Fazio P, Quint K, Hoffmann B, Scherübl H, Höpfner M.

Int J Oncol. 2012 Mar;40(3):876-88. doi: 10.3892/ijo.2011.1256. Epub 2011 Nov 7.

PMID:
22075556
15.

Management of early gastrointestinal neuroendocrine neoplasms.

Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G.

World J Gastrointest Endosc. 2011 Jul 16;3(7):133-9. doi: 10.4253/wjge.v3.i7.133.

16.

[Neuroendocrine neoplasms of the appendix and colorectum].

Klöppel G, Scherübl H.

Pathologe. 2011 Jul;32(4):314-20. doi: 10.1007/s00292-011-1438-y. Review. German.

PMID:
21655999
17.

Staging of rectal cancer by EUS: depth of infiltration in T3 cancers is important.

Jürgensen C, Teubner A, Habeck JO, Diener F, Scherübl H, Stölzel U.

Gastrointest Endosc. 2011 Feb;73(2):325-8. doi: 10.1016/j.gie.2010.10.026. Epub 2010 Dec 22.

PMID:
21176897
18.

Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management.

Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G.

World J Gastrointest Endosc. 2010 Oct 16;2(10):325-34. doi: 10.4253/wjge.v2.i10.325.

19.

Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?

Scherübl H, Cadiot G, Jensen RT, Rösch T, Stölzel U, Klöppel G.

Endoscopy. 2010 Aug;42(8):664-71. doi: 10.1055/s-0030-1255564. Epub 2010 Jul 28. Review.

PMID:
20669078
20.

[Neuroendocrine tumors of the stomach. Risk stratification and therapy].

Klöppel G, Scherübl H.

Pathologe. 2010 May;31(3):182-7. doi: 10.1007/s00292-009-1268-3. German.

PMID:
20306044
21.

[Neuroendocrine tumors of the small bowels are on the rise: early tumors and their management].

Scherübl H, Schwertner C, Steinberg J, Stölzel U, Pohl J, Dralle H, Klöppel G.

Z Gastroenterol. 2010 Mar;48(3):406-13. doi: 10.1055/s-0028-1109862. Epub 2010 Feb 24. Review. German.

PMID:
20183784
22.

Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.

Kulke MH, Scherübl H.

Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S62-6.

23.

[Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: good prognosis with early detection].

Scherübl H, Faiss S, Jahn HU, Liehr RM, Schwertner C, Steinberg J, Stölzel U, Weinke T, Zimmer T, Klöppel G.

Dtsch Med Wochenschr. 2009 Jul;134(30):1529-35. doi: 10.1055/s-0029-1233975. Epub 2009 Jul 14. Review. German.

PMID:
19603370
24.

[Rectal carcinoids on the rise - update].

Scherübl H, Klöppel G.

Z Gastroenterol. 2009 Apr;47(4):365-71. doi: 10.1055/s-2008-1027930. Epub 2009 Apr 8. Review. German.

PMID:
19358064
25.

Local therapy of rectal carcinoids: a matter of debate.

Scherübl H.

Arch Surg. 2009 Feb;144(2):195-6. doi: 10.1001/archsurg.2008.542. No abstract available.

PMID:
19221336
26.

Rectal carcinoids are on the rise: early detection by screening endoscopy.

Scherübl H.

Endoscopy. 2009 Feb;41(2):162-5. doi: 10.1055/s-0028-1119456. Epub 2009 Feb 12. Review.

PMID:
19214898
27.

Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

Hopfner M, Schuppan D, Scherubl H.

World J Gastroenterol. 2008 Dec 14;14(46):7021-32. Review.

28.

Tumor biology and prognosis of gastrointestinal carcinoids.

Scherübl H.

J Clin Oncol. 2008 Dec 20;26(36):6012-3; author reply 6013-5. doi: 10.1200/JCO.2008.19.9711. Epub 2008 Nov 17. No abstract available.

PMID:
19018074
29.

Comment on Ramage et al.: Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 2008;87:31-39.

Scherübl H.

Neuroendocrinology. 2008;88(3):157-8; author reply 158-9. doi: 10.1159/000158560. Epub 2008 Oct 9. No abstract available.

PMID:
18849621
30.
31.

Options for gastroenteropancreatic neuroendocrine tumours.

Scherübl H.

Lancet Oncol. 2008 Mar;9(3):203. doi: 10.1016/S1470-2045(08)70052-4. No abstract available.

PMID:
18308249
32.

Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.

Höpfner M, Schuppan D, Scherübl H.

World J Gastroenterol. 2008 Jan 7;14(1):1-14. Review.

33.

[Coincidental squamous cell cancers of the esophagus, head, and neck: risk and screening].

Scherübl H, Steinberg J, Schwertner C, Mir-Salim P, Stölzel U, de Villiers EM.

HNO. 2008 Jun;56(6):603-8. Review. German.

PMID:
17928979
34.
35.

[Coincidental squamous cell cancers of the esophagus and head and neck: risk and surveillance].

Steinberg J, Schwertner C, de Villiers EM, Mir-Salim P, Kiesslich R, Stoelzel U, Scherübl H.

Z Gastroenterol. 2007 Aug;45(8):710-4. Review. German.

PMID:
17701861
36.

The impersonator.

Lode H, Wagner J, Scherübl H.

Am J Med. 2007 Mar;120(3):239-41. No abstract available.

PMID:
17349446
37.

Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.

Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H.

Biochem Pharmacol. 2007 May 1;73(9):1308-17. Epub 2007 Jan 5.

PMID:
17266941
38.

Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.

Baradari V, Huether A, Höpfner M, Schuppan D, Scherübl H.

Endocr Relat Cancer. 2006 Dec;13(4):1237-50.

PMID:
17158768
39.

Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.

Hopfner M, Sutter AP, Huether A, Baradari V, Scherubl H.

World J Gastroenterol. 2006 Sep 21;12(35):5635-43.

40.

Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer.

Huether A, Hopfner M, Sutter AP, Baradari V, Schuppan D, Scherubl H.

World J Gastroenterol. 2006 Aug 28;12(32):5160-7.

41.

[Increased incidence of hepatocellular and intrahepatic cholangiocellular carcinoma in northeast Germany].

Schurr R, Stölzel U, Schuppan D, Schwertner C, Steinberg J, Scherübl H.

Dtsch Med Wochenschr. 2006 Jul 28;131(30):1649-55. German.

PMID:
16850381
42.

Ischemic enteritis caused by hepatitis C virus-associated polyarteritis nodosa.

Seja M, Wacker F, Scherubl H.

Clin Gastroenterol Hepatol. 2006 Nov;4(11):xxiv. Epub 2006 Jun 6. No abstract available.

PMID:
16757215
43.

The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.

Höpfner M, Baradari V, Huether A, Schöfl C, Scherübl H.

Endocr Relat Cancer. 2006 Mar;13(1):135-49.

PMID:
16601284
44.

Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.

Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherübl H.

Biochem Pharmacol. 2006 May 14;71(10):1435-48. Epub 2006 Mar 10.

PMID:
16530734
45.

Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.

Grabowski P, Sturm I, Schelwies K, Maaser K, Buhr HJ, Dörken B, Zeitz M, Daniel PT, Scherübl H.

Int J Colorectal Dis. 2006 Apr;21(3):221-30. Epub 2005 Jun 14.

PMID:
16485142
46.

Secretagogin is a novel marker for neuroendocrine differentiation.

Birkenkamp-Demtröder K, Wagner L, Brandt Sørensen F, Bording Astrup L, Gartner W, Scherübl H, Heine B, Christiansen P, Ørntoft TF.

Neuroendocrinology. 2005;82(2):121-38. Epub 2006 Jan 30.

PMID:
16449819
47.

DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.

Bhonde MR, Hanski ML, Budczies J, Cao M, Gillissen B, Moorthy D, Simonetta F, Scherübl H, Truss M, Hagemeier C, Mewes HW, Daniel PT, Zeitz M, Hanski C.

J Biol Chem. 2006 Mar 31;281(13):8675-85. Epub 2006 Jan 30.

48.

Double-balloon enteroscopy for the detection of midgut carcinoids.

Scherübl H, Faiss S, Tschöpe R, Zeitz M.

Gastrointest Endosc. 2005 Dec;62(6):994; author reply 994-5. No abstract available.

PMID:
16301062
49.

Tuberculous colitis.

Scherubl H, Zeitz M.

Gut. 2005 Dec;54(12):1820. No abstract available.

50.

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.

Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H.

Biochem Pharmacol. 2005 Nov 25;70(11):1568-78. Epub 2005 Oct 13.

PMID:
16226226

Supplemental Content

Loading ...
Support Center